During the COVID-19 pandemic, as an extraordinary measure, within the framework of fast-track recommendation development, based on the recommendation of the Minister of Health of 27 March 2020, the Agency prepared:
“Polish diagnostic, therapeutic and organizational recommendations for the care of individuals infected with SARS-CoV-2 or exposed to a SARS-CoV-2 infection” – version 1.0, 25 April 2020. (PL, EN)
Due to the rapidly changing pandemic situation and the constant influx of new scientific evidence confirming clinical effectiveness and safety of medical technologies applied in COVID-19, the Agency continuously updates the Recommendations.
Collection of updated COVID-19 recommendations:
- COVID-19 pharmacotherapy – updated Recommendations (version 2.9,14 September, 2021)
- COVID-19 diagnostics – updated Recommendations (version 2.1, 27 May 2021)
As part of the above activities, scientific report reviews (Rapid Reviews) concerning individual drug technologies applied in the case of COVID-19 (systemic corticosteroids, lopinavir administered in combination with ritonavir, remdesivir, tocilizumab, favipiravir, and convalescent plasma, anakinra, interferon beta, amantadine, hydroxychloroquine and chloroquine, anticoagulants, acetylsalicylic acid and clopidogrel, bamlanivimab, ivermectin, regdanvimab, REGN-COV2, sotrovimab, lenzilumab, baricitinib+remdesivir, inhaled corticosteroids, human immunoglobulin, baricitinib, mesenchymal stem cells, antibiotics, sarilumab, tofacitinib, sulodexide) have also been published. Analytical studies constitute the basis for the discussions conducted by the Panel of Clinical Experts.
*Ladies and Gentlemen
We inform you that the materials and results of the discussions posted on the Agency’s website are the result of the conceptual work and analytical process carried out by the team of the Agency for Health Technology Assessment and Tariff System based on the EBM paradigm, including: search, selection, synthesis and interpretation of scientific evidence, or the data analysis carried out .
In connection with the above, we would like to inform you that the use of analytical material or the results of the discussion, in accordance with good practice, should be accompanied by information on the source in the form: [title of presentation / report], AOTMiT, Warsaw, June 2021]